Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Laboratory MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prospective first-trimester screening for Trisomy 21 in 30,564 pregnancies.Am J Obstet Gynecol. 2005; 192: 1761-1767
- First-trimester or second-trimester screening, or both, for Down's syndrome.N Engl J Med. 2005; 353: 2001-2011
- Screening for fetal chromosomal abnormalities.(ACOG Practice Bulletin #27) The American College of Obstetricians and Gynecologists, Washington, DC2001
- Screening for fetal chromosomal abnormalities.(ACOG Practice Bulletin #27) The American College of Obstetricians and Gynecologists, Washington, DC2007
- Screening for Down syndrome: changing practice of obstetricians.Am J Obstet Gynecol. 2009; 200 (e1–9): 459
- Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome.BJOG. 2008; 115: 689-696
- Role of amniocentesis in the intrauterine detection of genetic disorders.N Engl J Med. 1970; 282: 596-599
- Efficient direct chromosome analyses and enzyme determinations from chorionic villi samples in the first trimester of pregnancy.Hum Genet. 1983; 63: 349-357
- An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities.Am J Obstet Gynecol. 1984; 148: 886-894
- Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.Obstet Gynecol. 1992; 80: 353-358
- Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.N Engl J Med. 1994; 330: 1114-1118
- Sonographic diagnosis of Down syndrome in the second trimester.Am J Obstet Gynecol. 1985; 153: 49-52
- The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia.BJOG. 2000; 107: 1453-1459
- Trends in the use of second trimester maternal serum screening from 1991 to 2003.Genet Med. 2005; 7: 328-331
- Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials.Am J Obstet Gynecol. 2006; 195: 236-239
- First-trimester screening for aneuploidy with fetal nuchal translucency in a United States population.Ultrasound Obstet Gynecol. 2003; 22: 149-151
- Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population?.Am J Obstet Gynecol. 2004; 190: 769-774
- Down syndrome screening in the United States in 2001 and 2007: a survey of maternal-fetal medicine specialists.Am J Obstet Gynecol. 2009; 201 (e1–5): 97
- Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995–2005.Am J Obstet Gynecol. 2007; 196 (e1–7): 315
- Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review.Prenat Diagn. 1999; 19: 808-812
- Trends in Down's syndrome live births and antenatal diagnoses in England and Wales from 1989 to 2008: analysis of data from the National Down Syndrome Cytogenetic Register.BMJ. 2009; 339: b3794
- The evolving national birth prevalence of Down syndrome in Taiwan. A study on the impact of second-trimester maternal serum screening.Prenat Diagn. 2005; 25: 665-670
- Centers for Disease Control and Prevention (CDC). Abortion surveillance—United States, 2006.MMWR Surveill Summ. 2009; 58: 1-35
- Abortion in the United States: incidence and access to services, 2005.Perspect Sex Reprod Health. 2008; 40: 6-16
- Gestational age at abortion: the impact of first-trimester risk assessment for aneuploidy.Am J Obstet Gynecol. 2006; 195: 839-842
- First- and second-trimester ultrasound assessment of gestational age.Am J Obstet Gynecol. 2004; 191: 975-978
- Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group.N Engl J Med. 1993; 329: 821-827
- Antenatal sonographic prediction of twin chorionicity.Am J Obstet Gynecol. 2006; 195: 863-867
- Performing a fetal anatomy scan at the time of first-trimester screening.Obstet Gynecol. 2009; 113: 402-407
- The nuchal translucency and the fetal heart: a literature review.Prenat Diagn. 2009; 29: 739-748
- Abortion for structural anomalies: the impact of early ultrasound.Am J Obstet Gynecol. 2009; 201: S156
- First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).Am J Obstet Gynecol. 2004; 191: 1446-1451
- Pregnancy-associated plasma protein A, free beta-hCG, nuchal translucency, and risk of pregnancy loss.Obstet Gynecol. 2004; 104: 30-36
- First-trimester biochemistry and outcomes in twin pregnancy.J Reprod Med. 2009; 54: 312-314
Article info
Publication history
Published online: June 16, 2010
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
